NEJM: Melanoma Drug Nearly Doubles Survival Time
A new drug to treat advanced skin cancer, or metastatic melanoma, has been shown to nearly double average survival time in a study of more than 130 patients, researchers said Wednesday.
Made by Genentech, a US subsidiary of the Swiss pharmaceutical giant Roche, the drug, Zelboraf, was approved by the U…


